Acute lymphoblastic leukaemia
Abstract
Acute lymphoblastic leukaemia, a malignant disorder of lymphoid progenitor cells, affects both children and adults, with peak prevalence between the ages of 2 and 5 years. Steady progress in development of effective treatments has led to a cure rate of more than 80% in children, creating opportunities for innovative approaches that would preserve past gains in leukaemia-free survival while reducing the toxic side-effects of current intensive regimens. Advances in our understanding of the pathobiology of acute lymphoblastic leukaemia, fuelled by emerging molecular technologies, suggest that drugs specifically targeting the genetic defects of leukaemic cells could revolutionise management of this disease. Meanwhile, studies are underway to ascertain the precise events that take place in the genesis of acute lymphoblastic leukaemia, to enhance the clinical application of known risk factors and antileukaemic agents, and to identify treatment regimens that might boost the generally low cure rates in adults and subgroups of children with high-risk leukaemia.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
ALL patients are treated with a combination of ~10 different chemotherapy agents through several phases lasting 2-3 years.
“ALL patients are treated with a combination of ~10 different chemotherapy agents through several phases lasting 2–3 years (Inaba et al., 2013; Pui, Robison, & Look, 2008; Pui et al., 2009).”
From Brain structure, working memory and response inhibition in childhood leukemia survivors (2017) · cites this paper as Pui, Robison, & Look, 2008
Cites
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760 · see citing works
Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9
Krivtsov, A. V., Twomey, D., Feng, Z., Stubbs, M. C., Wang, Y., Faber, J., Levine, J. E., Wang, J., Hahn, W. C., Gilliland, D. G., et al. (2006) · Nature · doi:10.1038/nature04980 · Cited by 1,513 · see citing works
Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis
Eischen, C. M., Weber, J. D., Roussel, M. F., Sherr, C. J., & Cleveland, J. L. (1999) · Genes & Development · doi:10.1101/gad.13.20.2658 · Cited by 819 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Cancer treatment and survivorship statistics, 2016
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066 · see citing works
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S. L., Payne-Turner, D., Easton, J., Chen, X., Wang, J., Rusch, M., et al. (2012) · Nature · doi:10.1038/nature10725 · Cited by 1,596 · see citing works
Self-citationDeletion of <i>IKZF1</i> and Prognosis in Acute Lymphoblastic Leukemia
Mullighan, C. G., Su, X., Zhang, J., Radtke, I., Phillips, L. A. A., Miller, C. B., Ma, J., Liu, W., Cheng, C., Schulman, B. A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808253 · Cited by 1,422 · see citing works
Self-citationL‐asparaginase treatment in acute lymphoblastic leukemia: A focus on <i>Erwinia</i> asparaginase
Pieters, R., Hunger, S. P., Boos, J., Rizzari, C., Silverman, L., Baruchel, A., Goekbuget, N., Schrappe, M., & Pui, C. (2011) · Cancer · doi:10.1002/cncr.25489 · Cited by 569 · see citing works
Self-citationL-asparaginase in the treatment of patients with acute lymphoblastic leukemia
Egler, R. A., Ahuja, S. P., & Matloub, Y. (2016) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.184769 · Cited by 334 · see citing works
Peirs, S., Matthijssens, F., Goossens, S., Van de Walle, I., Ruggero, K., de Bock, C. E., Degryse, S., Canté-Barrett, K., Briot, D., Clappier, E., et al. (2014) · Blood · doi:10.1182/blood-2014-05-574566 · Cited by 264 · see citing works
Molecular genetics of B-precursor acute lymphoblastic leukemia
Mullighan, C. G. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61203 · Cited by 247 · see citing works
Papayannidis, C., DeAngelo, D. J., Stock, W., Huang, B., Shaik, M. N., Cesari, R., Zheng, X., Reynolds, J. M., English, P. A., Ozeck, M., et al. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.80 · Cited by 122 · see citing works
Wu, S., Jiang, Y., Hong, Y., Chu, X., Zhang, Z., Tao, Y., Fan, Z., Bai, Z., Li, X., Chen, Y., et al. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01908-w · Cited by 81 · see citing works
Brain structure, working memory and response inhibition in childhood leukemia survivors
van der Plas, E., Schachar, R. J., Hitzler, J., Crosbie, J., Guger, S. L., Spiegler, B. J., Ito, S., & Nieman, B. J. (2017) · Brain and Behavior · doi:10.1002/brb3.621 · Cited by 59 · see citing works
Gagné, V., Rousseau, J., Labuda, M., Sharif-Askari, B., Brukner, I., Laverdière, C., Ceppi, F., Sallan, S. E., Silverman, L. B., Neuberg, D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1215 · Cited by 28 · see citing works
- Authors
- Pui, C.-H., Robison, L. L., & Look, A. T.
- Affiliations
- St. Jude Children's Research Hospital (US)
- Harvard University (US)
- Corresponding author
- Pui, Ching-Hon
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2008-03
- Volume
- 371
- Issue
- 9617
- Pages
- 1030-1043
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2105435030
- Cited by
- 1,564
- References
- 3
- Citations by year
- 2026: 29 · 2025: 49 · 2024: 65 · 2023: 62 · 2022: 66 · 2021: 55 · 2020: 74 · 2019: 73 · 2018: 89 · 2017: 100 · 2016: 102 · 2015: 101 · 2014: 124 · 2013: 93 · 2012: 127
- FWCI
- 17.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Sanofi
- National Cancer Institute (R01CA052259, CA 36401, CA90246, CA06516, CA 68484, CA 78224, CA-51001, P01CA068484, CA60419, CA21765, R01CA090246, R01CA078224, P30CA021765, P30CA006516, CA 52259)
- National Institute of Nursing Research (NR07610, R01NR007610)
- National Institute of General Medical Sciences (GM61393, U01GM061393)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Acute Lymphoblastic Leukemia research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
- Keywords
- acute lymphoblastic leukemia, pediatric leukemia, adult leukemia, targeted therapy, leukemogenesis, risk factors, treatment toxicity, cure rate
- MeSH terms
- Adolescent, Adult, Age Factors, Antineoplastic Agents, Child, Child, Preschool, Humans, Pharmacogenetics, Translocation, Genetic, Randomized Controlled Trials as Topic, Treatment Outcome, Risk Assessment, Disease-Free Survival, Precursor Cell Lymphoblastic Leukemia-Lymphoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
